Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population

Current Drug Safety

Volumn 5, Issue 3, 2010, Pages 190-193

  Efrati, Edna ^a   Elkin, Hela ^a   Sprecher, Eli ^a   Krivoy, Norberto ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

CYP2C9; HRM; Pharmacogenetics; Single nucleotide polymorphism; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; GENOMIC DNA; PROTEIN SUBUNIT; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

ALLELE; ARAB; ARTICLE; DRUG RESISTANCE; DRUG SENSITIVITY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INCIDENCE; ISRAEL; MOSLEM; NORMAL HUMAN; POPULATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VOLUNTEER; GENETICS; ISLAM; JEW; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ALLELES; ANTICOAGULANTS; ARABS; ARYL HYDROCARBON HYDROXYLASES; DRUG RESISTANCE; GENE FREQUENCY; GENOTYPE; HUMANS; ISLAM; ISRAEL; JEWS; MIXED FUNCTION OXYGENASES; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN; CYTOCHROME P-450 CYP2C9; VITAMIN K EPOXIDE REDUCTASES;

EID: 77954669309     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610791698299     Document Type: Article

References (30)

1. Zehnder J. Basic and Clinical Pharmacology. New York: McGraw Hill 2007; pp. 542-59.
2. Takahashi H, Wilkinson GR, Caraco Y, et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73(3): 253-63.
3. Zhao F, Loke C, Rankin SC, et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004; 76(3): 210-9.
4. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-50.
5. Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Human Mol Genet 2005; 14(13): 1745-51.
6. Geisen C, Watzka M, Sittinger K, et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005; 94(4): 773-9.
7. Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 2002; 36(10): 1512-7.
8. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med 2009; 24(5): 656-64.
9. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007; 121(1): 23-34.
10. D'Andrea G, D'Ambrosio R, Margaglione M. Oral anticoagulants: pharmacogenetics relationship between genetic and non-genetic factors. Blood Rev 2008; 22(3): 127-40.
11. Loebstein R, Dvoskin I, Halkin H, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007; 109(6): 2477-80.
12. Nakai K, Habano W, Nakai K, et al. Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations. Life Sci 2005; 78(1): 107-11.
13. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 2003; 33(Suppl 2): 23-30.
14. Scott SA, Edelmann L, Kornreich R, Desnick RJ. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 2008; 82(2): 495-500.
15. Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 2001; 79(10): 841-7.
16. Schelleman H, Chen Z, Kealey C, et al. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther 2007; 81(5): 742-7.
17. Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH. Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics 2007; 8(11): 1535-44.
18. Lee SC, Ng SS, Oldenburg J, et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 2006; 79(3): 197-205.
19. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254(3): 628-31.
20. Hill CE, Duncan A, Wirth D, Nolte FS. Detection and identification of cytochrome P-450 2C9 alleles *1, *2, and *3 by high-resolution melting curve analysis of PCR amplicons. Am J Clin Pathol 2006; 125(4): 584-91.
21. Carlquist JF, Horne BD, Muhlestein JB, et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006; 22(3): 191-7.
22. Zhu Y, Shennan M, Reynolds KK, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem 2007; 53(7): 1199-205.
23. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360(8): 753-64.
24. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358(10): 999-1008.
25. US FDA Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science. November 14-15, 2005 (www.fda.gov/ohrms/dockets/ac/cder05.html#PharmScience)
26. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106(7): 2329-33.
27. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008; 83(3): 460-70.
28. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105(2): 645-9.
29. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352(22): 2285-93.
30. Langley MR, Booker JK, Evans JP, McLeod HL, Weck KE. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn 2009; 11(3): 216-25.